Advertisement
Screener

MEDICINOVA, INC. (MNOV) Income (Loss) from Equity Method Investments

1.3 / 5 stars · 10/40 Roast Me

MEDICINOVA, INC. Income (Loss) from Equity Method Investments

MEDICINOVA, INC. (MNOV) reported Income (Loss) from Equity Method Investments of $19.87 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2020-02-13.

Discontinued › Income Statement › Other Income

us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2020-02-13

  • MEDICINOVA, INC. income (loss) from equity method investments for the quarter ending 2018-12-31 was $0.00.
  • MEDICINOVA, INC. income (loss) from equity method investments for the quarter ending 2018-09-30 was $0.00.
  • MEDICINOVA, INC. income (loss) from equity method investments for the quarter ending 2017-12-31 was $0.00.
  • MEDICINOVA, INC. income (loss) from equity method investments for the quarter ending 2017-09-30 was $0.00.
  • MEDICINOVA, INC. income (loss) from equity method investments for fiscal 2018 was $19.87K.
  • MEDICINOVA, INC. income (loss) from equity method investments for fiscal 2017 was -$1.67K.
  • MEDICINOVA, INC. income (loss) from equity method investments for fiscal 2016 was -$32.14K.
  • MEDICINOVA, INC. income (loss) from equity method investments for fiscal 2015 was -$34.32K, a 1001.47% decline from fiscal 2014.
Period endIncome (Loss) from Equity Method Investments 3 monthIncome (Loss) from Equity Method Investments 6 monthIncome (Loss) from Equity Method Investments 9 monthIncome (Loss) from Equity Method Investments 12 monthIncome (Loss) from Equity Method Investments 12 month as first filed
2018-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13
$0.00
derived: sum of 2 quarters · filed 2020-02-13
$19.87K
10-K · filed 2020-02-13
2018-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-24
$19.87K
10-Q · filed 2019-10-24
2018-06-30$19.87K
10-Q · filed 2019-07-25
2017-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13
$0.00
derived: sum of 2 quarters · filed 2019-02-13
$689.00
derived: sum of 3 quarters · filed 2019-02-13
-$1.67K
10-K · filed 2019-02-13
2017-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25
$689.00
derived: sum of 2 quarters · filed 2018-10-25
-$1.67K
10-Q · filed 2018-10-25
-$14.89K
derived: sum of 4 quarters · filed 2019-02-13
2017-06-30$689.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-23
-$1.67K
10-Q · filed 2018-07-23
-$14.89K
derived: sum of 3 quarters · filed 2019-02-13
-$18.86K
derived: sum of 4 quarters · filed 2019-02-13
2017-03-31-$2.36K
10-Q · filed 2018-04-25
-$15.58K
derived: sum of 2 quarters · filed 2019-02-13
-$19.55K
derived: sum of 3 quarters · filed 2019-02-13
-$34.49K
derived: sum of 4 quarters · filed 2019-02-13
2016-12-31-$13.22K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13
-$17.18K
derived: sum of 2 quarters · filed 2019-02-13
-$32.13K
derived: sum of 3 quarters · filed 2019-02-13
-$32.14K
10-K · filed 2019-02-13
2016-09-30-$3.97K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-23
-$18.91K
derived: sum of 2 quarters · filed 2017-10-23
-$18.92K
10-Q · filed 2017-10-23
-$28.87K
derived: sum of 4 quarters · filed 2018-02-13
2016-06-30-$14.94K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-26
-$14.95K
10-Q · filed 2017-07-26
-$24.90K
derived: sum of 3 quarters · filed 2018-02-13
-$44.17K
derived: sum of 4 quarters · filed 2018-02-13
2016-03-31-$13.00
10-Q · filed 2017-04-26
-$9.96K
derived: sum of 2 quarters · filed 2018-02-13
-$29.23K
derived: sum of 3 quarters · filed 2018-02-13
-$33.27K
derived: sum of 4 quarters · filed 2018-02-13
2015-12-31-$9.95K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13
-$29.22K
derived: sum of 2 quarters · filed 2018-02-13
-$33.26K
derived: sum of 3 quarters · filed 2018-02-13
-$34.32K
10-K · filed 2018-02-13
$34.32K
10-K · filed 2016-02-25
2015-09-30-$19.27K
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-25
-$23.31K
derived: sum of 2 quarters · filed 2016-10-25
-$24.37K
10-Q · filed 2016-10-25
-$29.91K
derived: sum of 4 quarters · filed 2017-02-14
2015-06-30-$4.04K
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-26
-$5.10K
10-Q · filed 2016-07-26
-$10.64K
derived: sum of 3 quarters · filed 2017-02-14
-$3.25K
derived: sum of 4 quarters · filed 2017-02-14
2015-03-31-$1.06K
10-Q · filed 2016-04-27
-$6.60K
derived: sum of 2 quarters · filed 2017-02-14
$790.00
derived: sum of 3 quarters · filed 2017-02-14
$4.44K
derived: sum of 4 quarters · filed 2017-02-14
2014-12-31-$5.54K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14
$1.85K
derived: sum of 2 quarters · filed 2017-02-14
$5.50K
derived: sum of 3 quarters · filed 2017-02-14
$3.81K
10-K · filed 2017-02-14
2014-09-30$7.39K
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-29
$11.04K
derived: sum of 2 quarters · filed 2015-10-29
$9.35K
10-Q · filed 2015-10-29
2014-06-30$3.65K
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-30
$1.96K
10-Q · filed 2015-07-30
2014-03-31-$1.69K
10-Q · filed 2015-05-11
2013-12-31$13.78K
10-K · filed 2015-03-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
NRX Pharmaceuticals, Inc. (NRXP)United States$0.131B-6.31
IMMUNIC, INC. (IMUX)United States$0.127B-1.88
Unicycive Therapeutics, Inc. (UNCY)United States$0.134B-3.70
TuHURA Biosciences, Inc./NV (HURA)United States$0.134B-4.88
INOVIO PHARMACEUTICALS, INC. (INO)United States$0.125B-1.35
Curanex Pharmaceuticals Inc (CURX)United States$0.138B
Aardvark Therapeutics, Inc. (AARD)United States$0.121B-1.80
CUMBERLAND PHARMACEUTICALS INC (CPIX)United States$0.121B-8.95
Coya Therapeutics, Inc. (COYA)United States$0.121B-6.35
Atrium Therapeutics, Inc. (RNA)United States$0.140B